The group lead by Prof. Sierra has extensive experience in conducting clinical trials in patients with haematological cancer, specifically acute myeloid leukaemia (AML), lymphoma and myeloma. Due to a dedicated clinical trial facility and medical expertise, our Institution has been chosen as a preferential partner by a worldwide leader CRO to conduct clinical trials in patients with haematological cancer, including acute leukaemia, lymphoma and myeloma.

Dr. Sierra is the President of the Spanish Society of Hematology, and Director of the CETLAM group, a Spanish leader scientific group in AML research. This group is heavily involved in the design and conduction of clinical trials in AML patients with novel therapies including monoclonal antibodies, a number of signalling pathways inhibitors, and allogeneic transplantation. Dr. Briones trained in immunology at Stanford University and has a significant experience in the development of novel preclinical gene therapy and immunotherapy projects for the treatment of leukemia and lymphoma, including national and international competitive projects on Immunotherapy with CAR T cells.  Dr. García-Cadenas, a clinician with extensive expertise in the treatment of patients with haematological cancer, was an immunology fellow at Würzburg University (Dr. Einsele’s lab) and she is actively working in CAR T cells immunotherapy projects in our institution..

Our group is actively involved in developing immunotherapy projects with CAR T cells targeting lymphoma and acute myeloid leukemia.

PAU will actively participate in the clinical trials activities, since they also offer a dedicated Phase I facility for first-in-man studies of drugs in patients with haematological malignancies. It will also be involved in the WP3 activities.

Prof. Jorge Sierra
Director, Hematology Service

Physician, Javier Briones
Chief section

Irene García-Cadenas
Staff Physician

PhD. Carmen Alvarez-Fernández Laura
Staff

PhD Laura Escribá García
Staff